慢性髓系白血病治疗新进展：第55届美国血液学会年会报道

Development of chronic myeloid leukemia in the 55th ASH annual meeting

慢性期慢性髓系白血病（CML-CP）患者在伊马替尼（IM）治疗得到稳定的完全分子生物学缓解（CMR）后,能否及何时安全停药成为第55届美国血液学会（ASH）年会的讨论热点.来自法国及澳大利亚著名的“停药试验”表明长期单用酪氨酸激酶抑制剂（TKI）不能治愈大部分CML患者.如何清除CML患者体内的残留病灶达到治愈以及长期的“无治疗缓解”和“无白血病生存”成为一线临床医师的关注点.文章就第55届ASH年会相关报道,阐述TKI靶向治疗时代CML潜在的联合治疗方法.

In patients with chronic myeloid leukemia （CML） in chronic phase who have achieved complete molecular remission on imatinib therapy,whether and when to discontinue the drug become a hot topic.The famous clinical trials of discontinue tyrosine kinase inhibitor （TKI） from France and Australia have demonstrated that long-term monotherapy with TKI is not curative in the majority of patients with CML.This has focused attention on strategies to eradicate residual disease in CML patients,which should result in cure and long-term treatment-free remission and leukemia-free survival.This review provides a brife summary of the 55th ASH annual meeting,focusing on the potential combination therapeutics in the era of TKI.